Kenvue Inc. (NYSE:KVUE) Receives Consensus Rating of “Hold” from Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned an average recommendation of “Hold” from the fifteen ratings firms that are currently covering the company, Marketbeat reports. Twelve equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $19.2727.

A number of research analysts recently commented on KVUE shares. Barclays upped their price objective on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group lowered their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Finally, Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th.

Kenvue Stock Performance

Shares of KVUE stock opened at $19.20 on Monday. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The business has a 50 day moving average of $18.95 and a two-hundred day moving average of $18.14. Kenvue has a 52 week low of $14.02 and a 52 week high of $21.84. The company has a market cap of $36.87 billion, a P/E ratio of 22.06, a PEG ratio of 1.37 and a beta of 0.47.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 earnings per share. As a group, analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be given a $0.21 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. This represents a $0.84 annualized dividend and a yield of 4.4%. Kenvue’s payout ratio is currently 96.55%.

Institutional Investors Weigh In On Kenvue

A number of hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership acquired a new stake in Kenvue in the 2nd quarter valued at approximately $6,528,000. Jump Financial LLC boosted its position in Kenvue by 210.6% during the 2nd quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after acquiring an additional 37,170 shares during the period. AXA S.A. boosted its position in Kenvue by 21.1% during the 2nd quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after acquiring an additional 8,524 shares during the period. NewEdge Advisors LLC grew its stake in shares of Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock worth $2,040,000 after purchasing an additional 66,930 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Kenvue by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock worth $39,217,000 after purchasing an additional 10,885 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.